# Kolon Life Science signs $200M supply deal for osteoarthritis drug Invossa-K

Kolon Life Science signed a 230 billion won ($200 million) contract to supply its osteoarthritis drug Invossa-K to China Life Medical Centre in Hainan Province, China. The contract was announced on July 18, 2018.

- Type: Contract
- Announced: 2018-07-18
- Where: Hainan Province, China
- Value: $200.0M (230.0B KRW)
- Status: announced
- Products: Invossa-K osteoarthritis drug

## Companies

- [Kolon Life Science](https://endata.com/companies/32675.md)
- [China Life Medical Centre](https://endata.com/companies/33181.md) (customer)

## Sources

- [biz.heraldcorp.com](https://biz.heraldcorp.com/article/1730026), 2018-07-17: "Kolon Life Science has signed a 230 billion won ($200 million) contract to export its osteoarthritis drug Invossa-K to China Life Medical Centre and Hainan Province."
- [pulse.mk.co.kr](https://pulse.mk.co.kr/news/english/8400684), 2018-07-18: "Korea’s Kolon Life Science has signed a 230 billion won ($200 million) contract to export its osteoarthritis drug Invossa-K to China Life Medical Centre and Hainan Province"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.